BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11943337)

  • 21. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
    Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
    Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
    Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
    Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
    Steinbach D; Schramm A; Eggert A; Onda M; Dawczynski K; Rump A; Pastan I; Wittig S; Pfaffendorf N; Voigt A; Zintl F; Gruhn B
    Clin Cancer Res; 2006 Apr; 12(8):2434-41. PubMed ID: 16638849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression.
    Bradbury DA; Zhu YM; Russell NH
    Leuk Lymphoma; 1997 Jan; 24(3-4):221-8. PubMed ID: 9156652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival.
    Khateeb EE; Morgan D
    Open Access Maced J Med Sci; 2015 Mar; 3(1):57-62. PubMed ID: 27275197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the
    Zhang F; Lu AD; Zuo YX; Ding MM; Jia YP; Zhang LP
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):543-549. PubMed ID: 35644195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
    Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
    Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
    Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
    Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
    Zhang YH; Lu AD; Yang L; Li LD; Chen WM; Long LY; Zhang LP; Qin YZ
    Leuk Res; 2017 Jan; 52():43-49. PubMed ID: 27875783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia.
    Skou AS; Juul-Dam KL; Hansen M; Lausen B; Stratmann S; Holmfeldt L; Aggerholm A; Nyvold CG; Ommen HB; Hasle H
    J Mol Diagn; 2021 Dec; 23(12):1787-1799. PubMed ID: 34600138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.
    van Baren N; Chambost H; Ferrant A; Michaux L; Ikeda H; Millard I; Olive D; Boon T; Coulie PG
    Br J Haematol; 1998 Sep; 102(5):1376-9. PubMed ID: 9753074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.
    Greiner J; Ringhoffer M; Taniguchi M; Li L; Schmitt A; Shiku H; Döhner H; Schmitt M
    Int J Cancer; 2004 Feb; 108(5):704-11. PubMed ID: 14696097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRAME expression in hairy cell leukemia.
    Arons E; Suntum T; Margulies I; Yuan C; Stetler-Stevenson M; Kreitman RJ
    Leuk Res; 2008 Sep; 32(9):1400-6. PubMed ID: 18295331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PRAME for acute myeloid leukemia therapy.
    Yang J; Chen M; Ye J; Ma H
    Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo.
    Xu Y; Yue Q; Wei H; Pan G
    Int J Clin Exp Pathol; 2015; 8(11):14549-55. PubMed ID: 26823776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.